Biotech

ImmunoPrecise announced it was awarded the first commercial humanizing antibody project from an undisclosed biotech company.

ImmunoPrecise Antibodies (TSXV:IPA; OTCPINK:IPATF) announced it was awarded the first commercial humanizing antibody project from an undisclosed biotech company.
As quoted in the press release:

This project builds on the Company’s recent R&D projects with two established biotech companies (see press release dated April 11, 2017) which produced successful results developing human monoclonal antibodies (see press release dated August 29, 2017) using its unique and proprietary methodologies, including its RapidPrime™ immunization protocol. ImmunoPrecise’s proprietary RapidPrime™ method identifies positive monoclonal antibodies in as little as 32 days.
“With this significant humanizing project award, we are expanding into one of the higher margin business segments we have been targeting and executing on one of our key strategic growth areas,” said Tom D’Orazio, CEO of ImmunoPrecise.

Click here to read the full press release.

Source: www.newswire.ca

MARKETS

Markets
TSX19578.30-90.87
TSXV663.83-4.45
DOW32774.41-58.13
S&P 5004122.47-17.59
NASD12493.93-150.53
ASX7020.60+5.00

COMMODITIES

Commodities
Gold1793.69+4.45
Silver20.51-0.19
Copper3.590.00
Palladium2223.00+2.00
Platinum936.50-7.50
Oil90.57+0.07
Heating Oil3.38+0.05
Natural Gas7.86+0.03

DOWNLOAD FREE REPORTS

×